08:00 , Mar 2, 2009 |  BC Week In Review  |  Company News

Dynogen gastrointestinal news

Dynogen Pharmaceuticals Inc. , Waltham, Mass.   Business: Gastrointestinal   Dynogen filed for Chapter 7 bankruptcy. Last year, Dynogen said it would seek private financing after its acquisition by special purpose acquisition company Apex Bioventures...
07:00 , Oct 20, 2008 |  BioCentury  |  Finance

Ebb & Flow

One mega biotech merger edged closer to completion last week, while the other remained opaque. Still, both ImClone (NASDAQ:IMCL) and Genentech (NYSE:DNA) continued to trade at a discount to their respective offer prices of $70...
07:00 , Apr 21, 2008 |  BC Week In Review  |  Company News

Dynogen, Apex Bioventures Acquisition Corp. deal

Special purpose acquisition company Apex and Dynogen terminated a deal under which Apex would have acquired Dynogen for $98 million in stock. The companies said they did not expect to attain shareholder approval for the...
07:00 , Apr 21, 2008 |  BioCentury  |  Finance

Ebb & Flow

Less than a month after completing its acquisition of cancer and infectious disease company Celldex in a stock deal for about $75 million, Avant (NASDAQ:AVAN) has received cash covering more than half of the purchase...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Company News

Dynogen, Apex Bioventures Acquisition Corp. deal

Special purpose acquisition company Apex will acquire Dynogen for $98 million in stock. Dynogen's shareholders will receive 13.5 million Apex shares for a 56% stake in the combined company, which will keep the name Dynogen...
08:00 , Feb 11, 2008 |  BioCentury  |  Finance

Ebb & Flow

Despite the proliferation of "Monday morning quarterbacking" on Biogen Idec's unfruitful attempt to sell itself late last year, President and CEO James Mullen last week reaffirmed his commitment to taking the company off the market....